Traditionally, clinical trials for asthma medications have skewed towards a narrow subset of patients who often do not reflect the complex realities of those suffering from severe asthma. Patients with overlapping conditions such as chronic obstructive pulmonary disease (COPD), smokers, adolescents, and Black/African American individuals have historically been excluded or underrepresented. By intentionally focusing on these groups, PASSAGE fills a critical gap, addressing the urgent need to understand how tezepelumab performs in populations where asthma management can be exceptionally challenging.

The underlying mechanism of tezepelumab involves the targeted inhibition of thymic stromal lymphopoietin (TSLP), an epithelial cytokine central to initiating multiple inflammatory pathways implicated in asthma pathogenesis. TSLP acts upstream in the inflammatory cascade, influencing both Type 2 and non-Type 2 inflammatory responses. This upstream blockade disrupts the activation of downstream effectors such as eosinophils, basophils, and T-helper type 2 (Th2) cells, which have been identified as key drivers of airway inflammation, hyperresponsiveness, and remodeling.

In the PASSAGE study, researchers enrolled a substantial cohort of 286 adults and adolescents with severe asthma, observing them over a one-year period to closely monitor safety, efficacy, and patient-reported outcomes. Notably, the frequency of asthma exacerbations dropped by an impressive 70% during tezepelumab treatment. This reduction was consistent across various phenotypes of asthma, underlining the therapy’s broad applicability. Lung function metrics, including forced expiratory volume in one second (FEV1), showed marked improvement, signalling better airway patency and reduced obstruction.

One of the study’s most salient findings is the effective management of severe asthma in smokers and those with concomitant COPD — groups that often present distinct diagnostic and therapeutic challenges due to overlapping symptoms and shared pathophysiological features. The amelioration in these patients’ respiratory health underscores tezepelumab’s versatility in targeting fundamental inflammatory pathways irrespective of these confounding factors, a feature that traditional corticosteroid therapies sometimes fail to address adequately.

Patient quality of life was another critical endpoint in PASSAGE. Through comprehensive qualitative interviews, treated individuals reported enhanced symptom control and greater satisfaction with their daily respiratory function. Reduced reliance on systemic corticosteroids, which are notorious for their adverse effect profile, was also documented, reflecting a shift towards safer long-term management strategies. This dimension of patient-centered outcomes reiterates the importance of incorporating real-world evidence to complement randomized controlled trial findings.

Safety data accrued during the PASSAGE trial reaffirmed tezepelumab’s reassuring profile. There were no novel or unexpected side effects observed over the course of treatment, alleviating concerns about its broader application in more vulnerable or multifaceted patient populations. The absence of severe adverse reactions supports tezepelumab’s position as a frontline biologic in severe asthma therapeutic regimens, particularly for those who have previously lacked suitable options due to coexisting conditions.

The success of tezepelumab in patients with Type 2 asthma, a subtype characterized by systemic eosinophilic inflammation, is of particular clinical significance. Type 2 asthma represents a substantial fraction of the severe asthma population, often marked by frequent exacerbations, chronic symptoms, and poor response to conventional inhaled corticosteroids alone. By mitigating TSLP-mediated inflammation upstream, tezepelumab offers a novel mechanism that circumvents some of the limitations associated with targeting single downstream cytokines, thus potentially translating into more durable control.

Beyond the immunological intricacies, the PASSAGE study extrapolates the critical role of real-world trials in complementing traditional research paradigms. While placebo-controlled, double-blind trials remain the gold standard, they often exclude the very patients clinicians encounter daily. PASSAGE bridges this divide by validating the drug’s efficacy and safety outside controlled environments, lending confidence to healthcare providers when prescribing tezepelumab to complex cases presenting in routine clinical practice.

Dr. Njira Lugogo, the study’s lead investigator and a clinical professor specializing in Pulmonary and Critical Care Medicine at the University of Michigan, emphasized the transformative potential of these findings. Highlighting the underrepresentation in prior studies, Dr. Lugogo expressed optimism that the inclusive design of PASSAGE and its compelling results will expedite more equitable asthma care. This approach not only advocates for diversity in clinical research but also signals a paradigm shift towards personalized medicine tailored to patient heterogeneity.

The implications of PASSAGE for asthma management guidelines and insurance frameworks cannot be understated. Demonstrating tezepelumab’s effectiveness in smoking populations and those with asthma-COPD overlap may prompt revisions in eligibility criteria and reimbursement policies, ensuring broader patient access to this life-altering therapy. As severe asthma continues to impose substantial morbidity and healthcare costs, such advances are pivotal in mitigating the global disease burden.

In summary, the PASSAGE study represents a landmark contribution to respiratory medicine, confirming that tezepelumab is a safe and efficacious option for severe asthma patients across diverse phenotypes and demographic groups. The study’s inclusion of underrepresented populations marks a crucial step toward closing the gap between clinical trial evidence and real-world clinical practice, providing hope for improved outcomes in patients who have historically been neglected in therapeutic research.

Subject of Research: Severe asthma treatment efficacy and safety of tezepelumab in diverse, underrepresented populations.

Article Title: Tezepelumab Demonstrates Broad Efficacy and Safety in Real-World Severe Asthma Across Underrepresented Populations: Insights from the PASSAGE Study.

News Publication Date: May 18, 2026.

Web References: https://academic.oup.com/ajrccm and https://ats2026.d365.events/education/sessions/6b19ba34-91df-4f14-8603-925bf88d033d

Image Credits: ATS

Keywords: Severe asthma, Tezepelumab, Biologics, Phase 4 clinical trial, PASSAGE study, TSLP inhibition, Underrepresented populations, Asthma-COPD overlap, Type 2 asthma, Real-world evidence, Lung function, Safety profile.

Severe asthma is characterized by persistent inflammation of the airways, leading to recurring symptoms that are often resistant to standard treatments. The overarching goal of treatment is to achieve clinical remission, where the patient’s symptoms are minimized or eradicated entirely. However, determining whether a patient is in remission is not a straightforward process; the criteria are often ambiguous and can vary widely among patients.

The study highlights a significant issue: the absence of a universally accepted definition of clinical remission in severe asthma. Current definitions often depend on subjective assessments of symptoms, lung function tests, and a patient’s quality of life. This inconsistency poses a significant challenge for healthcare providers striving to implement effective treatment plans tailored to individual patient needs.

Moreover, the research delves into various metrics used to gauge clinical remission, underscoring the complexity of evaluating patient outcomes. Metrics such as the Asthma Control Test (ACT) and forced expiratory volume (FEV1) are commonly employed but do not always capture the full spectrum of a patient’s health status. This gap can lead to misinterpretation of remission, wherein a patient may appear to be in remission based solely on numerical scores, yet continue to experience diminished quality of life.

In addition to the evaluation tools, the Mayo Clinic study brings attention to the role of comorbid conditions in assessing asthma remission. Many patients with severe asthma also suffer from other chronic conditions such as obesity, depression, and allergic rhinitis. These comorbidities complicate the clinical picture, making it difficult to ascertain whether asthma treatment alone is responsible for symptom alleviation or if other health issues are at play.

Furthermore, the research presents the notion that psychological factors may significantly influence perceptions of asthma control and remission. Patients’ beliefs about their disease and its management may drive their reporting of symptoms, creating discrepancies between subjective experiences and clinical assessments. Educating patients on the nature of their condition and treatment can therefore be crucial in achieving better outcomes.

Another essential aspect the study discusses is the impact of medication adherence on achieving remission. Non-adherence to prescribed therapies is prevalent among asthma patients, often stemming from misunderstandings about medication purpose and side effects. This results in suboptimal treatment outcomes and can falsely indicate the need for more intensive therapies when, in fact, better adherence may offer the relief needed.

Additionally, the study also examines the significance of regular follow-up visits in the management of severe asthma. Frequent assessments allow healthcare providers to monitor disease progression, re-evaluate treatment plans, and ensure that patients remain engaged in their treatment process. This continuous dialogue helps foster a therapeutic alliance between patients and healthcare teams, directly contributing to better management outcomes.

The authors advocate for a more nuanced approach to defining and evaluating remission. They propose a comprehensive model that combines physiological measurements, patient-reported outcomes, and contextual factors into a singular assessment framework. This holistic approach could lead to more precise definitions of clinical remission and, ultimately, better personalized treatment strategies for patients.

The implications of this research extend beyond individual patient care. A standardized approach to evaluating clinical remission could also influence clinical trials and regulatory measures, ensuring that future studies adhere to a more rigorous definition of success. As the field of asthma research continues to evolve, collaboration among researchers, clinicians, and patients will be crucial in creating a unified front in the fight against severe asthma.

Overall, the findings presented by Lim and colleagues at the Mayo Clinic not only challenge existing paradigms of asthma management but also pave the way for future advancements in the field. The complexity of evaluating clinical remission in severe asthma demands ongoing attention, refinement of criteria, and a commitment to patient-centered care.

Shaping a future where patients with severe asthma can lead fulfilling lives devoid of debilitating symptoms hinges upon the collective efforts of the medical community to address these challenges head-on. As we move forward, the insights gained from this research will undoubtedly fuel discussions on best practices, innovative treatments, and the ultimate goal of achieving true clinical remission for all patients.

Subject of Research: Challenges in Evaluating Clinical Remission in Severe Asthma

Article Title: Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic

Article References:

Lim, K., Deb, A., Corbridge, T. et al. Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic.
Adv Ther (2025). https://doi.org/10.1007/s12325-025-03433-y

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12325-025-03433-y

Keywords: Severe asthma, clinical remission, asthma control, patient adherence, comorbid conditions.